Objectives: To analyse the mechanisms responsible for multidrug resistance in three carbapenem-resistant Klebsiella pneumoniae isolates recovered from two hospitalized patients and an outpatient from the same hospital in Rabat, Morocco.
Introduction
Carbapenem-hydrolysing b-lactamases belonging to Ambler classes A, B and D are increasingly reported worldwide among Enterobacteriaceae. 1 Whereas KPC-type (class A) producers are mostly identified in the USA, Greece and Israel, OXA-48 (class D) producers are mostly from the Mediterranean area, including Morocco. 1, 2 Recently the class B b-lactamase NDM-1 has become a source of serious concern. 3 Initially identified from Klebsiella pneumoniae and Escherichia coli isolates recovered in Sweden from a patient previously hospitalized in India, 4 NDM-1 producers have subsequently been identified in the UK, India and Pakistan, and identified in K. pneumoniae, E. coli, Citrobacter freundii, Morganella morganii, Providencia spp. and Enterobacter cloacae isolates. 3 Additionally, many studies have reported identification of NDM-1-producing enterobacterial isolates in different parts of the world. NDM-1 producers have been identified in the Middle East, with two K. pneumoniae from the Sultanate of Oman and one from Iraq, and one Acinetobacter baumannii isolate producing NDM-2 from Egypt. 3, 5 Very recently, NDM-1 producers were found in seepage samples and public tap water in New Delhi, India, showing that the dissemination of these multidrug-resistant bacteria might be higher than expected. 6 This study was initiated following isolation of multiresistant K. pneumoniae from three patients (two inpatients and one outpatient) attending the same hospital in Rabat, Morocco.
Materials and methods
Bacterial isolates and susceptibility testing K. pneumoniae isolates were identified using the API20E system (bioMér-ieux, Marcy l'Étoile, France). Strain isolation and identification were performed locally in Morocco and strains were then further analysed in France. The antibiotic susceptibility of each isolate and their corresponding E. coli transformants was determined using the disc diffusion technique on Mueller-Hinton agar plates with b-lactam and non-b-lactam antibiotic-containing discs and interpreted according to the CLSI guidelines. 7 Azide-resistant E. coli J53 (Invitrogen, Cergy-Pontoise, France) was used as a host in conjugation experiments. 2 
PCR amplification and sequencing
PCRs were performed with a series of primers designed for the detection of Ambler class A, B and C b-lactamase genes. 2 Screening of 16S rRNA methylase-encoding genes was performed using a multiplex PCR approach as described previously. 8 Amplified DNA fragments were 
Plasmid analysis
Conjugation assays were performed using each of the three K. pneumoniae clinical isolates as donors and an azide-resistant E. coli J53 as the recipient strain. Selection of transconjugants was undertaken by plating on MuellerHinton agar containing cefoxitin (10 mg/L) and azide (100 mg/L). 2 Plasmid incompatibility groups were determined by a PCR-based replicon typing method (PBRT) as described previously. 9 
Strain genotyping
Multilocus sequence typing (MLST) was performed as described previously. 10 In addition, PFGE was performed using the XbaI restriction enzyme to evaluate the clonal relationship between the different NDM-1 producers.
Results and discussion
Isolate 1 was from the urine of an elderly male patient hospitalized in a medical department who had previously received broad-spectrum cephalosporins and fluoroquinolones for recurrent urinary tract infections. Once the K. pneumoniae strain was isolated, the treatment was changed to amikacin and colistin, and the patient recovered. This patient had a history of prior hospitalization 1 month before in the same hospital in the surgery and intensive care departments for treatment of vessel cancer. Isolate 2 was recovered 10 days later from a blood culture of an aplastic female in her 60s who was hospitalized in the same hospital and in the same intensive care department. She was treated with imipenem and metronidazole, but died. This patient had a history of prior hospitalization 1.5 months before in the same hospital in the surgery department for treatment of throat cancer and hospitalization in another hospital 15 days before. Isolate 3 was recovered from a pancreatic abscess of a middle-aged female patient who was an outpatient from the same hospital. This patient had been hospitalized in another hospital for treatment of this pancreatic abscess. No information is available concerning her treatment and outcome.
The three isolates had the same antibiotic susceptibility pattern, being susceptible to imipenem and doripenem with MICs of 1 mg/L, of intermediate susceptibility to meropenem with MICs of 2 mg/L and resistant to ertapenem with MICs of 4 mg/L. They were also resistant to aminoglycosides (except to amikacin, being of intermediate susceptibility), fluoroquinolones, chloramphenicol, sulphonamides and rifampicin. They remained susceptible to fosfomycin, tigecycline, colistin and nitrofurantoin. The three isolates were positive for bla NDM , and sequencing revealed that they were producing NDM-1.
PFGE analysis showed an identical pattern for all isolates. The clonal relationship was further confirmed by MLST, which showed that the three K. pneumoniae isolates belonged to the same sequence type (ST), ST15. Notably, bla CTX-M-15 -positive but bla NDM-1 -negative K. pneumoniae strains of ST15 have been found to be endemic both in Hungary and Denmark. 11, 12 No screening for carriage of other NDM-1 producers was performed among neighbouring hospitalized patients since the K. pneumoniae isolates were analysed retrospectively. A search for narrow-spectrum b-lactamase, extendedspectrum b-lactamase (ESBL) and AmpC genes revealed that all isolates harboured the narrow-spectrum b-lactamase genes bla TEM-1 , bla SHV-1 , bla OXA-1 and bla OXA-9 , together with two ESBL genes, namely bla SHV-5 and bla CTX-M-15 . However, they did not harbour AmpC-encoding genes or 16S rRNA methylase-encoding genes.
Transferability of the bla NDM-1 gene was studied by conjugation experiments using one K. pneumoniae isolate as the donor and E. coli J53 as the recipient strain. Transconjugant E. coli J53 (pMAR) expressing NDM-1 was obtained, being resistant to all b-lactams, including aztreonam (for which a synergy was determined with clavulanate), and having decreased susceptibility to carbapenems [MICs of imipenem, meropenem, ertapenem and doripenem being 1, 1, 2 and 0.5 mg/L, respectively (the MICs of these compounds being 0.12 mg/L for the E. coli J53 recipient strain)]. The E. coli transconjugants were also resistant to tobramycin and chloramphenicol. PCR analysis confirmed that plasmid pMAR co-harboured the bla NDM-1 , bla OXA-1 and bla CTX-M-15 genes. Plasmid analysis revealed an 250 kb plasmid that was non-typeable using PBRT. A history of contacts with or origin of the patients from the Indian subcontinent were not in evidence here. This study now reports NDM-1 producers in North Africa, a region considered as endemic for OXA-48 producers.
Interestingly, the plasmid identified here carried both bla NDM-1 and bla CTX-M-15 genes, in contrast to what we previously observed among a collection of NDM-1-and CTX-M-15-producing isolates of worldwide origin (Australia, France, Germany, India, Iraq, Kenya, Oman and Switzerland), in which these two genes were located on two different plasmids. 13 Finally, this report identified the spread of NDM-1-producing K. pneumoniae isolates in Morocco. Two of the three patients were treated in the same hospital units (surgery and intensive care departments), which probably allowed for inter-patient spread of the strain. This report indicates that NDM-1 producers may circulate worldwide further than expected.
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